• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Daily citalopram associated with decreased agitation in Alzheimer’s disease

byJonathan Lichkus
February 19, 2014
in Chronic Disease, Neurology, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Daily treatment with citalopram in patients with probable Alzheimer disease was associated with decreased agitation compared to placebo.

2. Citalopram use in Alzheimer’s disease patients is associated with QTc interval prolongation and worse Mini-Mental Status Exam scores. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Previous research has suggested that citalopram, a selective serotonin reuptake inhibitor, may be a potential substitute for antipsychotic drugs when treating agitation in patients with Alzheimer’s disease (AD). This study (Citalopram for Agitation in Alzheimer Disease Study, CitAD) aimed to determine the effect of citalopram on patients’ functional abilities and elucidate any safety concerns. The study results suggest that treatment with citalopram significantly decreased agitation on two standardized scales. It should be noted, however, that citalopram use was also associated with QTc interval prolongation and significantly lower Mini-Mental Status Exam (MMSE) scores.  This study is important for identifying a potentially clinically relevant treatment effect using citalopram, but its use in everyday practice may be limited by safety concerns.

Click to read the study, published today in JAMA 

Click to read the accompanying editorial in JAMA

RELATED REPORTS

Wellness Check: Sleep

The 2 Minute Medicine Podcast Episode 6

Lecanemab may slow cognitive decline in early Alzheimer’s disease

Relevant Reading: Management of agitation and aggression associated with Alzheimer disease

In-Depth [randomized controlled trial]: This multi-center, double-blind, placebo-controlled trial randomized 186 patients with probable AD (defined by the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer Disease and Related Disorders Association criteria) to receive either nine weeks of citalopram or placebo. At 9 weeks, these participants had significantly lower scores on the NBRS-A scale (Neurobehavorial Rating Scale-Agitation, mean -0.93, 95%CI -1.80 to -0.06,p=0.04). In addition, 40% of treated participants had much or very much improved mADCS-CGIC (modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change) scores compared to 26% of participants in the placebo group (OR 2.13, 95%CI 1.23-3.69, p=0.007). However, participants using citalopram were also significantly more likely to have lower MMSE (Mini-Mental Status Exam) scores (p=0.03), report diarrhea (p=0.03), and have an increased QTc interval (p=0.004).

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Alzheimer’s diseasecitalopram
Previous Post

Diffusion-weighted MRI shows promise as a radiation-free alternative for pediatric tumor staging

Next Post

Poor fetal growth in overweight & obese with insufficient weight gain

RelatedReports

Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

March 16, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 6

February 9, 2023
Free alternatives comparable to Mini-Mental State Examination
Chronic Disease

Lecanemab may slow cognitive decline in early Alzheimer’s disease

January 10, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

March 14, 2023
Next Post

Poor fetal growth in overweight & obese with insufficient weight gain

Home-based exercise after hip fracture rehabilitation improves mobility and balance

Home-based exercise after hip fracture rehabilitation improves mobility and balance

Malarial transmission substantially reduced in endemic Africa

Malarial transmission substantially reduced in endemic Africa

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options